Exploring Polypharmacology of BCR-ABL Inhibitors
Exploring Polypharmacology of BCR-ABL Inhibitors
Created using ChatSlide
This study explores the background and rationale behind drug repurposing in chronic myeloid leukemia (CML), focusing on BCR-ABL biology and TKI polypharmacology. It employs an integrative informatics methodology utilizing data from PubChem, CTD, and CMap, alongside cheminformatics and pathway analysis. The results highlight insights into imatinib and nilotinib pathways, proposing antifibrotic and CNS-related repurposing hypotheses. The study concludes with consensus findings, validation...